Answer
Vedolizumab has a serum half-life of 26 days, based on population pharmacokinetic analyses of intravenous and subcutaneous data.
Sources for this answer
- Entyvio 300 mg powder for concentrate for solution for infusionTakeda UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 17Document updated
Sources checked